Lyn Jones

Lyn Jones is an accomplished scientist with extensive experience in chemical biology and medicinal chemistry. Currently serving as Chief Scientist at the Dana-Farber Cancer Institute since September 2019, Lyn Jones directs the Center for Protein Degradation, focusing on innovative drug discovery modalities. Prior to this role, Lyn Jones was Vice President and Head of Chemistry and Chemical Biology at Jnana Therapeutics, contributing to the establishment of the company and co-inventing the RAPID platform. Lyn Jones’ tenure at Pfizer spanned over 16 years in various leadership roles within chemical biology and medicinal chemistry. Lyn Jones' early research efforts included a postdoctoral position at Scripps Research, where important discoveries in antibody-catalyzed pathways were made, and a placement year at Sandoz focused on immunosuppressive rapalogs. Lyn Jones holds a PhD in Synthetic Organic Chemistry from the University of Nottingham and a BSc (Hons) in Chemistry from the University of Bath.